Trial · NCT04356716
Sildenafil for Treatment of Choroidal Ischemia
NCT04356716, Phase 2, Completed, Columbia University; results first posted 2025-07-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sildenafil for Treatment of Choroidal Ischemia. Trials, record NCT04356716. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04356716
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sildenafil for Treatment of Choroidal Ischemia
- NCT number
- NCT04356716
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 22 participants, actual
- Lead sponsor
- Columbia University
- Conditions
- Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
- Interventions
- Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A), Visual Acuity (VA)
- First posted
- 2020-04-22
- Last updated
- 2025-07-04
- Results first posted
- 2025-07-04
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Visual Acuity (Sildenafil Group) | Up to 63 months | Patients are evaluated for progression of disease/dystrophy via visual acuity (improved/stable/worsened) and appearance of fluid layer and drusen on OCT testing. |
| Primary | Change in Visual Acuity (Medical Record Review Group) | 22 months | Patients are evaluated for progression of disease/dystrophy via visual acuity (improved/stable/worsened) and appearance of fluid layer and drusen on OCT testing. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Visual Acuity (Sildenafil Group) | Up to 63 months | logMAR | MEAN | |
| PRIMARY | Change in Visual Acuity (Medical Record Review Group) | 22 months | logMAR | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Visual Acuity (Sildenafil Group) | Sildenafil | Right eyes | 0.00 | Standard Deviation 0.21 | logMAR |
| Change in Visual Acuity (Sildenafil Group) | Sildenafil | Left eyes | -0.03 | Standard Deviation 0.36 | logMAR |
| Change in Visual Acuity (Medical Record Review Group) | Medical Record Review | Right eye | 0.00 | logMAR | |
| Change in Visual Acuity (Medical Record Review Group) | Medical Record Review | Left eye | 0.00 | logMAR |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Sildenafil | 21 | |
| Overall Study | STARTED | Medical Record Review | 1 | |
| Overall Study | COMPLETED | Sildenafil | 21 | |
| Overall Study | COMPLETED | Medical Record Review | 1 | |
| Overall Study | NOT COMPLETED | Sildenafil | 0 | |
| Overall Study | NOT COMPLETED | Medical Record Review | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Sildenafil | 0 | 21 |
| Total, all-cause mortality | Medical Record Review | 0 | 0 |
| Total, other adverse events | Sildenafil | 0 | 21 |
| Total, other adverse events | Medical Record Review | 0 | 0 |
| Total, serious adverse events | Sildenafil | 0 | 21 |
| Total, serious adverse events | Medical Record Review | 0 | 0 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04356716
GET https://conductscience.org/api/trials/v1/NCT04356716/registered